Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Biological Heart Valves and Arteries for Children

Technology #20120236

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Heart ValvesPediatric Cardiovascular SurgeryDecellularization
Categories
Researchers
Robert Tranquillo, Ph.D.
External Link (bme.umn.edu)
Zeeshan Syedain, Ph.D.
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

US Patent Pending 20140058496

US Patent Pending 20150164631
Publications
Tissue engineering of acellular vascular grafts capable of somatic growth in young lambs
Nature Communications, 27 September 2016

Engineered Heart Valves and Arteries for Children’s Hearts

A method to create heart valves and arteries for use in patients who require narrow tubes for long-term implantation has been developed. The process begins by trapping fibroblasts from skin tissue in fibrin gel, and then molding, conditioning and decellularizing the gel. Decellularization leaves the extracellular matrix of the tissue, which can be modified into durable, small-diameter tubes for implantation. When surgically inserted, the tubes recellularize to take on the characteristics of surrounding tissue and assimilate to the cardiovascular structure. The tubes collapse at three anchor points, replicating valve function of natural arteries. The recellularization of the valves allows for the tube to grow as the patient matures, making them ideal for use in patients who have not fully developed into adulthood.

MN-IP Try and Buy
This technology is available via a standard negotiated license agreement. Contact Raj Udupa for specific details.

Current Artificial Heart Valve too Large for Pediatric Cardiovascular Surgery

As the number of heart valve implant surgeries in America reaches 95,000 annual procedures, there is an increasing need for techniques aimed toward the grafting and repair of small diameter arteries. Current artificial heart valve implants use synthetic materials and cell sheets to create tubes for surgical grafting into the heart. These kinds of valves are not well suited for small-diameter tubes (<6mm) and cannot be used in procedures on infants or children. Completely biological grafts that create narrow diameter valves for arterial implants would revolutionize pediatric cardiovascular surgery.

BENEFITS OF FULLY BIOLOGICAL HEART VALVES AND ARTERIES:

  • Smaller diameter is optimal for use in younger patients
  • Able to be grown in only 7 weeks
  • Recellularization lets the tissue grow with the patient
  • Has already been tested with favorable results

Related Technologies